Noom Introduces GLP-1 Drug Option in Innovative Weight Loss Program
Noom, a digital health company, has announced a new weight loss product featuring a compounded GLP-1 drug starting at $149. The treatment includes compounded semaglutide, the same active ingredient in Novo Nordisk’s Wegovy and Ozempic drugs. Noom is offering this alternative to help meet the increasing demand for weight loss and diabetes medications. Several digital health companies have also recently launched similar programs, emphasizing the need for more affordable options in the market.
Compounded GLP-1 medications are custom-made alternatives to branded drugs like Wegovy and Ozempic, offering a more cost-effective option for consumers. While branded drugs can cost around $1,000 per month, compounded versions are typically much cheaper. Noom’s program will cost consumers $149 for the first month and $279 for subsequent months as the medication dosage increases.
It is important to note that the FDA does not review the safety and efficacy of compounded products, although they do inspect some outsourcing facilities that compound drugs. Noom is working with an FDA-regulated compounding pharmacy to provide its medication for the program, known as Noom GLP-1 RX. The company is confident in the vetting process and has also introduced a way for participants to taper off the treatment if desired.
Participants in the Noom GLP-1 RX program will receive personalized support from obesity-trained doctors, coaches, and clinicians. They will also have access to psychology-based programming and tools to help with weight loss and muscle maintenance. Noom aims to drive sustained weight loss outcomes, offering a free year of Noom or medication discounts to those who regain weight within 18 months after following the program for a year. Participants can sign up for the program on the website and receive the medication within a week of approval by a doctor.
SOURCE
Emily Jensen, graduated from the London School of Economics and Political Science (LSE) in the UK in 2015 with a degree in Economics. She specializes in financial markets and international trade. After graduating, she worked as an analyst at an investment bank in London, where she developed expertise in global economic trends. She later transitioned into consulting, focusing on fintech ventures and providing insights into global economic developments. Emily is passionate about the intersection of finance and technology and aims to drive innovation in the financial sector.